Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for Treatment of Refractory Chronic Lymphocytic Leukemia

Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

(2010) A. M. Evens et al.   ANNALS OF ONCOLOGY

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

(2010) William G. Wierda et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma

(2009) B. Li et al.   BLOOD

Plasma quantitation of JAK2 mutation is not suitable as a clinical test: an artifact of storage

(2009) M. E. Salama et al.   BLOOD

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

(2008) A. Hagenbeek et al.   BLOOD

Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody

(2008) Wim K. Bleeker et al.   BRITISH JOURNAL OF HAEMATOLOGY

Chronic lymphocytic leukaemia

(2008) G Dighiero et al.   LANCET